Patent application number | Description | Published |
20090136446 | INDUCTION OF REGULATORY T CELL-RESISTANT HELPER CD4+ T CELLS - The invention relates to stimulation of immune responses against antigen(s) and overcoming regulatory T cell suppression of such immune responses against antigen(s). | 05-28-2009 |
20090137782 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 05-28-2009 |
20090263394 | A34 AND A33-LIKE 3 DNA PROTEIN, ANTIBODIES THERETO AND METHODS OF TREATMENT USING SAME - Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient. | 10-22-2009 |
20090324651 | Methods for Stimulating an Immune Response Using Bacterial Antigen Delivery System - The invention relates to the use of the type III secretion system of bacteria to stimulate immune responses against tumor antigen(s) for treating antigen-loss variant tumors. Methods are provided for stimulating and/or increasing an immune response against tumor antigens. The invention also relates to the preparation of antigen presenting cells from peripheral blood mononuclear cells using bacteria having a type III secretion system. | 12-31-2009 |
20100324319 | Tame based chelators and uses thereof - New bifunctional chelation complexes are described. These are based on the structure of the so-called “TAME-HexA” molecule. The compounds are especially useful for forming chelation complexes with metal ions, including radioisotopes. | 12-23-2010 |
20110076232 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 03-31-2011 |
20110097271 | Colon Cancer Associated Transcript 1 (CCAT1) As A Cancer Marker - The present invention relates to the identification, isolation, and sequencing of a unique nucleic acid transcript termed Colon Cancer Associated Transcript 1 (CCAT-1) that is specifically expressed in cancer cells, in particular in colon, rectal, and lung cancer, as well as in precancerous lesions. The present invention thus provides methods for diagnosing cancer by detecting the expression of CCAT-1 as well as isolated polynucleotides, compositions and kits for use in the detection methods of the invention. | 04-28-2011 |
20110129483 | Membrane transporter NaPi2b (SCL34A1) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy - The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide (s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided. | 06-02-2011 |
20110182944 | Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein - The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts. | 07-28-2011 |
20110293511 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 12-01-2011 |
20110313230 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 12-22-2011 |
20120039892 | A34 AND A33-LIKE 3 DNA PROTEIN, ANTIBODIES THERETO AND METHODS OF TREATMENT USING SAME - Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient. | 02-16-2012 |
20120183471 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 07-19-2012 |
20120231035 | METHOD FOR INDUCING CELL LYSIS WITH IMMUNOGENIC PORTIONS OF NY-ESO-1 PROTEIN - The invention relates to peptides which bind to MHC Class I and to MHC Class II molecules. These peptides are useful in different therapeutic and diagnostic contexts. | 09-13-2012 |
20120283115 | SEROMIC ANALYSIS OF OVARIAN CANCER - The invention relates to the discovery of cancer antigens associated with ovarian cancer. In further aspects, the invention relates to methods, compositions and kits for the diagnosis and treatment of cancer, particularly ovarian and pancreatic cancers. | 11-08-2012 |
20120328660 | IMMUNOGENIC COMPOSITIONS USEFUL IN PROVOKING AN INTEGRATED RESPONSE TO TUMOR ANTIGENS - The invention relates to an immunogenic composition and its use. It comprises “OLPs,” or overlapping peptides, derived from a longer, tumor antigen, in combination with polyICLC, and Montanide. | 12-27-2012 |
20130266573 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 10-10-2013 |
20140193417 | Membrane Transporter NaPi2b (SCL34A2) Epitope for Antibody Therapy, Antibodies Directed Thereto, and Target for Cancer Therapy - The present disclosure relates generally to the membrane transporter NaPi2b (SLC34A2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The SLC34A2 epitope peptide encompassing amino acids 312-340 of SLC34A2 has been identified as an ovarian cancer epitope using the monoclonal antibody MX35. The invention also relates to the use of SLC34A2 and particularly SLC34A2 peptides in generating antibodies which have anti-tumor or anti-cancer activity or in stimulating an immunological response. The invention further relates to antibodies specifically directed against NaPi2b (SLC34A2) and the SLC34A2 peptide(s), including veneered, chimeric, single chain and humanized antibodies. Methods for generating an immune response and for treatment of tumors and cancer are also provided. Assays for screening and identifying compounds directed against SLC34A2, including the SLC34A2 epitope peptide, and additional antibodies are provided. | 07-10-2014 |
20140255410 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 09-11-2014 |
20140255436 | IMMUNOGENIC COMPOSITIONS USEFUL IN PROVOKING AN INTEGRATED RESPONSE TO TUMOR ANTIGENS - The invention relates to an immunogenic composition and its use. It comprises “OLPs,” or overlapping peptides, derived from a longer, tumor antigen, in combination with polyICLC, and Montanide. | 09-11-2014 |
20140322130 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 10-30-2014 |
Patent application number | Description | Published |
20090164932 | Logging And Evaluating Manual Interactions By Users To Support Optimizing And Streamlining Business Processes - The subject matter disclosed herein provides methods and apparatus, including computer program products, for logging and evaluating activity to support optimizing and streamlining a process, such as a business process. In one aspect, there is provided a computer-implemented method. The method include receiving information representative of activity at a user interface. The received information may be aggregated to form aggregated data. The received information may be evaluated to determine one or more proposals. The evaluation may use the context of a task being performed at the user interface and the activity at the user interface. The one or more proposals may be provided to enable a configuration of a system or a business process with at least one of the proposals. Related apparatus, systems, methods, and articles are also described. | 06-25-2009 |
20130111381 | Modeling Properties of Data and Events as Transformations of Document Data and System Values | 05-02-2013 |
20130151571 | INTERFACE DEFINED VIRTUAL DATA FIELDS - According to one general aspect, a method may include receiving a virtual data field definition from a user interface model. The virtual data field may include a data field does not have a counterpart in a database of actual data fields. The method may include dynamically generating the virtual data field based upon the virtual data field definition. The method may include responding to a data request from the user interface with a plurality of data fields, wherein the plurality of data fields include both the virtual data field and an actual data field included by the database. | 06-13-2013 |
20130159356 | FIELD TRANSFORMATIONS FOR USER INTERFACE DATA ELEMENTS - A method and system, the method may include determining a user interface to be displayed, the user interface including a user interface data element associated with a service input parameter. Information about the service input parameter may be provided to a field transformation as a transformation input, and a transformation output may be received from the field transformation. | 06-20-2013 |
20130166596 | USER INTERFACE MODEL DRIVEN DATA ACCESS CONTROL - According to one general aspect, a method of retrieving data entities from a backend data device may include maintaining a data model of data entities employed by a user interface. The data model may include a hierarchical relationship between a leading data entity and at least one child data entity. The method may also include authorizing, with an authorization device, when retrieving the leading data entity. The method may include instructing the authorization device that data retrievals of subsequent data entities are to be authorized based upon the authorization of the leading data entity. The method may also include retrieving at least one child data entity of the leading data entity without providing additional authorization credentials. | 06-27-2013 |
20140157154 | MANAGING BUSINESS OBJECTS - In accordance with aspects of the disclosure, a system and methods are provided for managing business objects in memory. The system and methods may be provided for defining a context of one or more input parameters of data used to determine one or more properties of one or more business objects, defining one or more rules associated with the one or more properties of each business object, and generating a metadata model for each business object based on the context of the one or more input parameters of each business object and the one or more rules associated with the one or more properties of each business object. | 06-05-2014 |
20140337384 | Modeled Authorization Check Implemented with UI Framework - Access by a user to a database layer, is governed by modeled authorization checking implemented with authorization objects present in an overlying application layer. At design time, the authorization checking is modeled as part of an existing user interface (UI) model, which may conform to a Model, View, and Control (MVC) design pattern. Authorization objects created during design time, are stored in a meta data repository. At runtime, an authorization engine references the authorization objects and the operations supported by those authorization objects. The authorization check is thus implemented centrally in the UI framework itself using this modeled information. Embodiments avoid complexity, potential lack of internal consistency, and low visibility of conventional de-centralized authorization checking schemes that rely upon a plurality of enforcement points hard-coded at multiple locations within application logic. | 11-13-2014 |
20140372863 | TEMPORARY HIGHLIGHTING OF SELECTED FIELDS - Approaches are presented for temporary highlighting of selected fields of a document. For example, a user can select which fields of a document or class of documents he wishes to have highlighted. The user can also select (a) when he wishes the selected fields to be highlighted, for example, if a field exceeds a threshold and/or (b) how he wishes the selected fields to be highlighted, e.g., overlay the field with a contrasting color. When the user performs a specified action, for example, opens a document, the selected field is selectively highlighted according to the rules for when and how to highlight the selected field. This can help a user quickly recognize important fields in the context of the document. | 12-18-2014 |